Clinical Trial

Effects of Sulforaphane for Patients With Chronic Kidney Disease

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Patients with Chronic Kidney Disease (CKD) have many complications associated with inflammation, oxidative stress and intestinal dysbiosis, which are closely related to the progression of kidney failure and cardiovascular disease. Sulforaphane, an isothiocyanate found in cruciferous vegetables (Family: Brassicaceae) is recognized as one of the most important activators of erythroid nuclear factor 2 related to factor 2 (Nrf2). However, clinical evidence to assess the effects of sulforaphane in patients with CKD is scarce, and there are no studies that have investigated its effects on the expression of genes and markers related to inflammation in these patients. Thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of sulforaphane on transcription factors and inflammatory markers in patients with CKD.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-10-25; most recent amendment 2025-04-01.
Status change: Recruiting → Active, Not Recruiting 2024-02-23
Status change: Not Yet Recruiting → Recruiting 2022-01-04
Trial Details
NCT Number NCT04608903
Lead Sponsor Universidade Federal Fluminense
Conditions Chronic Kidney Disease
Enrollment 25 participants
Start Date 2021-12-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-03